TEM
Tempus AI, Inc. Class A Common Stock
About: Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Employees: 2,300
0
Funds holding %
of 6,815 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
59% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 27
53% more call options, than puts
Call options by funds: $78.1M | Put options by funds: $51.2M
42% more capital invested
Capital invested by funds: $1.49B [Q2] → $2.12B (+$629M) [Q3]
28% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 18
20% more funds holding
Funds holding: 80 [Q2] → 96 (+16) [Q3]
20% more funds holding in top 10
Funds holding in top 10: 5 [Q2] → 6 (+1) [Q3]
1.46% less ownership
Funds ownership: 26.66% [Q2] → 25.2% (-1.46%) [Q3]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$52
63%
upside
Avg. target
$62
93%
upside
High target
$74
132%
upside
7 analyst ratings
4 positive
57%
3 neutral
43%
0 negative
0%
Loop Capital Mark Schappel 65% 1-year accuracy 20 / 31 met price target | 63%upside $52 | Buy Maintained | 14 Jan 2025 |
Needham Ryan MacDonald 56% 1-year accuracy 38 / 68 met price target | 76%upside $56 | Buy Reiterated | 14 Jan 2025 |
B of A Securities Michael Ryskin 75% 1-year accuracy 3 / 4 met price target | 70%upside $54 | Neutral Maintained | 13 Dec 2024 |
Wolfe Research Doug Schenkel 40% 1-year accuracy 2 / 5 met price target | 89%upside $60 | Outperform Initiated | 13 Dec 2024 |
Guggenheim Subbu Nambi 50% 1-year accuracy 4 / 8 met price target | 132%upside $74 | Buy Initiated | 9 Dec 2024 |
Financial journalist opinion
Based on 18 articles about TEM published over the past 30 days
Neutral
Zacks Investment Research
17 hours ago
TEM Stock Declines Following Preliminary Q4 Sales Miss
Tempus reports strong 2024 growth and unveils a bold 2025 outlook with 75% revenue growth and innovative diagnostics.
Neutral
Business Wire
18 hours ago
Tempus One Introduces New GenAI Capabilities to Query Millions of Unstructured Documents for Research and Clinical Care
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today introduced a suite of new, transformative capabilities available in Tempus One, the company's generative AI assistant. Tempus One, which initially launched in 2023, provides both physicians and researchers AI-enabled services that leverage generative AI to propel privacy-enabled, data-driven decision support in the clinic while simultaneo.
Neutral
Business Wire
1 day ago
Tempus Announces Its First-Ever, Whole-Genome Sequencing Assay, xH
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is developing its first whole-genome sequencing test, xH. This test marks Tempus' first foray into adopting whole-genome sequencing (WGS) as a platform, supporting clinicians with detection of all clinically-relevant variants and advancing the landscape of personalized therapy, specifically in hematological oncology.
Neutral
Business Wire
1 day ago
Tempus Announces Preliminary Fourth Quarter and Full Year 2024 Results
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced select, preliminary, unaudited results for the fourth quarter and full year ended December 31, 2024. Full Year 2024 Select, Preliminary, Unaudited Financial Results Revenue of approximately $693 million, representing approximately 30% growth year-over-year Continued improvement in adjusted EBITDA compared to the prior year Fourt.
Positive
24/7 Wall Street
3 days ago
2 Stocks Cathie Wood Is Swinging For the Fences With
Investing guru Cathie Wood remains an investor favorite.
Positive
Zacks Investment Research
5 days ago
Tempus AI Stock Falls Despite Collaboration Announcement With Genialis
TEM announces a collaboration with Genialis to develop new RNA-based algorithms across cancer types.
Neutral
Business Wire
6 days ago
Tempus Announces a Collaboration With Genialis to Develop RNA-Based Biomarker Algorithms
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, the RNA-biomarker company. The multi-year agreement allows Genialis to leverage Tempus' multimodal dataset to develop new RNA-based algorithms across cancer types. Clinical care for cancer patients is hindered by insufficient biomarkers that fail to accurately predict patient response to treatment.
Positive
Zacks Investment Research
1 week ago
Tempus AI Stock Surges 23% in 6 Months: Should You Snap It Up Now?
TEM's cutting-edge product lines and strategic plans are positioning it for long-term success.
Neutral
Business Wire
1 week ago
Tempus to Present at 43rd Annual J.P. Morgan Healthcare Conference
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the 43rd Annual J.P. Morgan Healthcare on January 13-16, 2025, in San Francisco, CA. Company Presentation | Tempus Founder and CEO, Eric Lefkofsky, will deliver a presentation and host a Q&A with the investment community at the conference on Monday, January 13. Panel with Chief Scientific Officer, Kate Sasser | Policy Ou.
Positive
Zacks Investment Research
2 weeks ago
5 Top AI-in-MedTech Stocks for Big Gains in 2025: MDT, BSX & More
Here we discuss five medical stocks - MDT, BSX, BDX, GEHC and TEM - incorporating AI in their workflows. These are likely to gain in 2025 as AI helps cut costs and improve patient care.
Charts implemented using Lightweight Charts™